Hypothyroidism overview: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m Template |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Hypothyroidism}} | {{Hypothyroidism}} | ||
{{CMG}} | {{CMG}} {{AE}} | ||
==Overview== | ==Overview== | ||
'''Hypothyroidism''' is the disease state in human and animals caused by insufficient production of [[thyroid hormone]] by the [[thyroid gland]]. It affects about 5% of the United Kingdom population over 60 years of age. As of 2006, more than 1% of the United Kingdom population were receiving T<sub>4</sub> ([[Thyroxine]]) replacement therapy for hypothyroidism.<ref name="tjcemjul06">{{cite journal |author=Grozinsky-Glasberg S, Fraser A, Nahshoni E, Weizman A, Leibovici L |title=Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials |journal=J. Clin. Endocrinol. Metab. |volume=91 |issue=7 |pages=2592-9 |year=2006 |month=July |pmid=16670166 |doi=10.1210/jc.2006-0448}}</ref> | '''Hypothyroidism''' is the disease state in human and animals caused by insufficient production of [[thyroid hormone]] by the [[thyroid gland]]. It affects about 5% of the United Kingdom population over 60 years of age. As of 2006, more than 1% of the United Kingdom population were receiving T<sub>4</sub> ([[Thyroxine]]) replacement therapy for hypothyroidism.<ref name="tjcemjul06">{{cite journal |author=Grozinsky-Glasberg S, Fraser A, Nahshoni E, Weizman A, Leibovici L |title=Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials |journal=J. Clin. Endocrinol. Metab. |volume=91 |issue=7 |pages=2592-9 |year=2006 |month=July |pmid=16670166 |doi=10.1210/jc.2006-0448}}</ref> | ||
==Historical Perspective== | |||
==Classification== | |||
==Pathophysiology== | |||
==Causes== | |||
==Differentiating {{PAGENAME}} from Other Diseases== | |||
==Epidemiology and Demographics== | |||
==Risk Factors== | |||
==Screening== | |||
==Natural History, Complications, and Prognosis== | |||
===Natural History=== | |||
===Complications=== | |||
===Prognosis=== | |||
==Diagnosis== | |||
===Diagnostic Criteria=== | |||
===History and Symptoms=== | |||
===Physical Examination=== | |||
===Laboratory Findings=== | |||
===Imaging Findings=== | |||
===Other Diagnostic Studies=== | |||
==Treatment== | |||
===Medical Therapy=== | |||
===Surgery=== | |||
===Prevention=== | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WS}} | |||
{{WH}} | |||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
Latest revision as of 19:40, 27 June 2016
|
Hypothyroidism Main page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Overview
Hypothyroidism is the disease state in human and animals caused by insufficient production of thyroid hormone by the thyroid gland. It affects about 5% of the United Kingdom population over 60 years of age. As of 2006, more than 1% of the United Kingdom population were receiving T4 (Thyroxine) replacement therapy for hypothyroidism.[1]
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hypothyroidism overview from Other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Natural History
Complications
Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
References
- ↑ Grozinsky-Glasberg S, Fraser A, Nahshoni E, Weizman A, Leibovici L (2006). "Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials". J. Clin. Endocrinol. Metab. 91 (7): 2592–9. doi:10.1210/jc.2006-0448. PMID 16670166. Unknown parameter
|month=ignored (help)